Elevated KIM-1 Levels Associated With Poor Prognosis in mRCC | GU Oncology Now
High KIM-1 may be a biomarker of poor prognosis in RCC and correlates with specific LOF mutations, transcriptions programs.
High KIM-1 may be a biomarker of poor prognosis in RCC and correlates with specific LOF mutations, transcriptions programs.
The study will assess the overall response to olutasidenib plus azacitidine in higher-risk MDS, CMML, and advanced MPNs.
Find key news and updates in thoracic oncology from the 2025 ASCO Annual Meeting, taking place May 30 to June 3, 2025, in Chicago, Illinois.
The 2025 American Society of Clinical Oncology Annual Meeting in Chicago will feature key research and treatment updates for nurses and advanced practitioners in oncology.
Discover the truth about anti-aging myths. Learn how lifestyle, exercise, diet, and supplements really work for healthy aging.
Several ROS1 tyrosine kinase inhibitors (TKIs) have been explored as first-line therapies for patients with advanced ROS1 fusion–positive non–small cell lung cancers. Only 3 TKIs…
Plant-based proteins—especially tempeh—can help reduce insulin resistance, improve blood sugar and support long-term metabolic health.
Recent research highlights the significance of Omega-3 […]
Research presented at the British Cardiovascular Societ […]
Adopting the MIND diet, even later in life, is associated with a reduced risk of developing dementia. As the U.S. population grows older and dementia…
As science advances and awareness deepens, plant-based proteins will no longer stand in the shadows of tradition